Cargando…
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
Hyperuricemia is a feature of several pathologies and requires an appropriate and often early treatment, owing to the severe consequences that it may cause. A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damag...
Autores principales: | Cammalleri, Lisa, Malaguarnera, Mariano |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838823/ https://www.ncbi.nlm.nih.gov/pubmed/17396159 |
Ejemplares similares
-
Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)
por: Pession, Andrea, et al.
Publicado: (2008) -
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017) -
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
por: Dinnel, Jennifer, et al.
Publicado: (2015) -
Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series
por: Latha, S. M., et al.
Publicado: (2015) -
Rasburicase-Induced Falsely Low Measurement of Uric Acid in Tumor Lysis Syndrome: A Report of Two Cases
por: Yu, Lian, et al.
Publicado: (2023)